The final product is an emulsion of MCWF in squalane in phosphate\buffered saline. (2SC); 5?mL Amplimune intramuscularly (5IM); 5?mL Amplimune subcutaneously (5SC); 5?mL saline intramuscularly (SalIM) and 5?mL saline subcutaneously (SalSC) on day 0 following transportation. Body temperature, body weight, concentrations of circulating pro\inflammatory cytokines (TNF, IL\1, IL\6 and IL\12) and haematology parameters were measured at numerous occasions up to 96?h post\treatment. Results No adverse effects from Amplimune treatment were observed. Amplimune induced an increase in circulating cytokine TNF concentrations, total white blood cell count and lymphocyte counts indicative of activation of the innate immune system without causing an excessive inflammatory response. Conclusions Results confirm that Amplimune can be safely administered to beef cattle at the dose rates and via the routes of administration investigated here. fermentation productsTNFtumour necrosis factor alphaWBCwhite blood cell Disease is usually a major cost to the beef cattle feedlot industry in Australia. 1 The Australian feedlot industry is investing in research to reduce disease incidence, reduce reliance on antibiotics and improve animal health and welfare outcomes. 2 Bovine respiratory disease (BRD) is responsible for Rabbit Polyclonal to RNF149 the majority of veterinary treatments and health\related mortalities in Australian feedlots. 3 It is estimated to reduce earnings by between $67.10 and $1647.53 per animal if there are subclinical or clinical symptoms, or the animal dies. 3 Stress is well documented to have a suppressive effect on the immune response in livestock. 4 Consequently, stressors imposed by transportation, induction procedures at a feedlot, switch in diet and surroundings, increased human handling and co\habitation with unfamiliar animals are all classified as risk factors that predispose cattle to BRD. 4 , 5 , 6 , 7 In addition, factors such as breed, excess weight and season in which cattle are launched to the feedlot can affect their risk of BRD. 8 Feedlot productivity and profitability could benefit from strategies to reduce the incidence and reduce reliance on antimicrobials to treat disease. Commercial vaccines are available in Australia to protect cattle against the major causal pathogens of BRD including and only 0.2% were pre\vaccinated against bovine herpes computer virus\1. 9 Though the proportion of animals pre\vaccinated against BRD entering Australian feedlots has thought to have increased in the last decade, CC-930 (Tanzisertib) as suggested by a CC-930 (Tanzisertib) rise in seropositivity to bovine herpes computer virus\1 at feedlot access from 0.2% to 13.5%, it remains the case that a significant proportion of cattle entering Australian feedlots receive their first BRD vaccination at feedlot induction. 10 For cattle that are not pre\vaccinated, it is common practice for feedlot operators to vaccinate against BRD at induction. However, there are limitations CC-930 (Tanzisertib) to the ability of vaccination at induction to provide full protection against BRD. Firstly, there is a variable time lapse between vaccination and the establishment of protective responses, leaving a space in which cattle are not fully guarded. Secondly, targeting every pathogen associated with BRD via vaccines has not yet been achieved and may not be achievable given the complexity of the contamination. Currently, Australian feedlot operators rely on antibiotics to treat BRD. 6 , 11 Although evidence to suggest any significant contribution of antibiotic use in agriculture to the rise in antibiotic resistance in human pathogens is lacking, the use of antibiotics in food\producing animals is usually coming under increasing scrutiny. 12 Some consumers of animal protein are concerned by a perceived association between the use of antibiotics in livestock production and the rise in antibiotic resistance. 12 If consumers become dissatisfied with a component of a product, demand for the product decreases, damaging those markets. Despite this, there is increasing worldwide demand for animal\based protein, which is expected to drive a predicted 67% increase in the use of antibiotics in livestock production systems by 2030. 12 Zelnate?, an immune stimulant based on bacterial DNA and cationic lipids, is usually registered for the treatment of and to reduce mortality and lung lesions associated with BRD in America, 13 but there is.